{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:43:48Z","timestamp":1787021028406,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The gabapentinoids pregabalin and mirogabalin are utilized to treat neuropathic pain, especially in patients with cancer receiving opioid analgesics. Pregabalin combined with strong opioids increases somnolence and dizziness, while mirogabalin causes fewer central adverse events. This study aimed to determine whether mirogabalin leads to a lower incidence of somnolence and dizziness than pregabalin in patients with cancer receiving strong opioids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed inpatients with cancer treated with mirogabalin or pregabalin along with strong opioids at Fujita Health University Hospital (April 2019\u2013December 2023) and assessed cumulative incidence rates, hazard ratios (HRs) for somnolence and dizziness occurrence, and changes in morphine milligram equivalents (MMEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 89 patients included in the analysis (mirogabalin: 39, pregabalin: 50), the median time to somnolence and dizziness was significantly shorter in the mirogabalin group than in the pregabalin group (8.0 vs. 17.0 days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.039). The multivariable Cox proportional regression model showed a higher risk with mirogabalin, although with no significance (HR: 1.74,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.117). MMEs increased in the pregabalin group but not in the mirogabalin group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mirogabalin and pregabalin contribute to somnolence and dizziness in patients receiving strong opioids, necessitating careful monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-025-00464-z","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:17:53Z","timestamp":1751354273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incidence of somnolence and dizziness induced by mirogabalin and pregabalin under opioid treatment: a single-center observational study"],"prefix":"10.1186","volume":"11","author":[{"given":"Hitoshi","family":"Iwasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenao","family":"Koseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"1","key":"464_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40122-021-00255-y","volume":"10","author":"Y Kimura","year":"2021","unstructured":"Kimura Y, Yamaguchi S, Suzuki T, Kato J, Chiba S, Hirakawa N, et al. Switching from Pregabalin to Mirogabalin in patients with peripheral neuropathic pain: A Multi-Center, prospective, Single-Arm, Open-Label study (MIROP study). Pain Ther. 2021;10(1):711\u201327.","journal-title":"Pain Ther"},{"issue":"5","key":"464_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMp1704633","volume":"377","author":"CW Goodman","year":"2017","unstructured":"Goodman CW, Brett AS. Gabapentin and Pregabalin for Pain - Is increased prescribing a cause for concern?? N Engl J Med. 2017;377(5):411\u20134.","journal-title":"N Engl J Med"},{"key":"464_CR3","first-page":"303","volume":"8","author":"B Parsons","year":"2015","unstructured":"Parsons B, Emir B, Clair A. Temporal analysis of pain responders and common adverse events: when do these first appear following treatment with Pregabalin. J Pain Res. 2015;8:303\u20139.","journal-title":"J Pain Res"},{"issue":"2","key":"464_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","volume":"73","author":"CP Taylor","year":"2007","unstructured":"Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73(2):137\u201350.","journal-title":"Epilepsy Res"},{"issue":"3","key":"464_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1124\/jpet.117.247551","volume":"365","author":"Y Domon","year":"2018","unstructured":"Domon Y, Arakawa N, Inoue T, Matsuda F, Takahashi M, Yamamura N, et al. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the \u03b1(2)\u03b4 subunit of Voltage-Gated calcium channels. J Pharmacol Exp Ther. 2018;365(3):573\u201382.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"464_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3344\/kjp.2021.34.1.4","volume":"34","author":"JY Kim","year":"2021","unstructured":"Kim JY, Abdi S, Huh B, Kim KH. Mirogabalin: could it be the next generation Gabapentin or pregabalin? Korean J Pain. 2021;34(1):4\u201318.","journal-title":"Korean J Pain"},{"issue":"8","key":"464_CR7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/AJP.0000000000000310","volume":"32","author":"J Guan","year":"2016","unstructured":"Guan J, Tanaka S, Kawakami K. Anticonvulsants or antidepressants in combination pharmacotherapy for treatment of neuropathic pain in Cancer patients: A systematic review and Meta-analysis. Clin J Pain. 2016;32(8):719\u201325.","journal-title":"Clin J Pain"},{"key":"464_CR8","doi-asserted-by":"publisher","first-page":"1009950","DOI":"10.3389\/fphar.2022.1009950","volume":"13","author":"J Hahn","year":"2022","unstructured":"Hahn J, Jo Y, Yoo SH, Shin J, Yu YM, Ah YM. Risk of major adverse events associated with gabapentinoid and opioid combination therapy: A systematic review and meta-analysis. Front Pharmacol. 2022;13:1009950.","journal-title":"Front Pharmacol"},{"key":"464_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40780-015-0022-7","volume":"1","author":"H Kato","year":"2015","unstructured":"Kato H, Miyazaki M, Takeuchi M, Tsukuura H, Sugishita M, Noda Y, Yamada K. A retrospective study to identify risk factors for somnolence and Dizziness in patients treated with Pregabalin. J Pharm Health Care Sci. 2015;1:22.","journal-title":"J Pharm Health Care Sci"},{"key":"464_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40780-015-0032-5","volume":"1","author":"A Ohishi","year":"2015","unstructured":"Ohishi A, Chisaki Y, Hira D, Nagasawa K, Terada T. Opioid analgesics increase incidence of somnolence and Dizziness as adverse effects of pregabalin: a retrospective study. J Pharm Health Care Sci. 2015;1:30.","journal-title":"J Pharm Health Care Sci"},{"issue":"7","key":"464_CR11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.31083\/ph.2024.4528","volume":"79","author":"H Kato","year":"2024","unstructured":"Kato H, Koseki T, Kondo M. Occurrence of somnolence and respiratory depression induced by Pregabalin and Mirogabalin use and the influence of opioid treatment using the Japanese adverse drug event report database. Pharmazie. 2024;79(7):169\u201372.","journal-title":"Pharmazie"},{"key":"464_CR12","doi-asserted-by":"crossref","unstructured":"Hanamoto A, Koseki T, Utsunomiya A, Ishihara T, Tobe T, Kondo M et al. Influence of brain metastasis on Analgesia-Related outcomes in patients with lung and breast cancers treated with naldemedine: A propensity Score-Matched analysis. J Clin Med. 2023;12(22).","DOI":"10.3390\/jcm12226997"},{"issue":"3","key":"464_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"464_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/papr.12045","volume":"14","author":"E Raptis","year":"2014","unstructured":"Raptis E, Vadalouca A, Stavropoulou E, Argyra E, Melemeni A, Siafaka I. Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. Pain Pract. 2014;14(1):32\u201342.","journal-title":"Pain Pract"},{"issue":"5","key":"464_CR15","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/cam4.3779","volume":"10","author":"J Dai","year":"2021","unstructured":"Dai J, Teng L, Zhao L, Zou H. The combined analgesic effect of Pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study. Cancer Med. 2021;10(5):1738\u201344.","journal-title":"Cancer Med"},{"issue":"17","key":"464_CR16","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1080\/14656566.2021.1958780","volume":"22","author":"J Kato","year":"2021","unstructured":"Kato J, Inoue T, Yokoyama M, Kuroha M. A review of a new voltage-gated Ca(2+) channel \u03b1(2)\u03b4 ligand, mirogabalin, for the treatment of peripheral neuropathic pain. Expert Opin Pharmacother. 2021;22(17):2311\u201322.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"464_CR17","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1177\/21925682211031185","volume":"13","author":"T Akazawa","year":"2023","unstructured":"Akazawa T, Inoue G, Tanaka M, Umehara T, Nagai T, Oshita Y, et al. Somnolence and Dizziness during Mirogabalin treatment in patients with neuropathic pain related to lumbar disease who switched from pregabalin: A retrospective study. Global Spine J. 2023;13(5):1319\u201324.","journal-title":"Global Spine J"},{"issue":"9","key":"464_CR18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/14740338.2023.2193395","volume":"22","author":"R Nakajima","year":"2023","unstructured":"Nakajima R, Ooba N, Kamei M, Hashiba H, Miyazaki C. Safety of Mirogabalin and Pregabalin in Japanese patients with neuropathic pain: a retrospective cohort study. Expert Opin Drug Saf. 2023;22(9):841\u20138.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"464_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40122-020-00156-6","volume":"9","author":"M Baba","year":"2020","unstructured":"Baba M, Kuroha M, Ohwada S, Murayama E, Matsui N. Results of Mirogabalin treatment for diabetic peripheral neuropathic pain in Asian subjects: A phase 2, Double-Blind, randomized, Placebo-Controlled, study. Pain Ther. 2020;9(1):261\u201378.","journal-title":"Pain Ther"},{"issue":"3","key":"464_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/0091270003251119","volume":"43","author":"EJ Randinitis","year":"2003","unstructured":"Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of Pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003;43(3):277\u201383.","journal-title":"J Clin Pharmacol"},{"key":"464_CR21","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2147\/JPR.S255345","volume":"13","author":"M Baba","year":"2020","unstructured":"Baba M, Takatsuna H, Matsui N, Ohwada S. Mirogabalin in Japanese patients with renal impairment and pain associated with diabetic peripheral neuropathy or Post-Herpetic neuralgia: A phase III, Open-Label, 14-Week study. J Pain Res. 2020;13:1811\u201321.","journal-title":"J Pain Res"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00464-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00464-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00464-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:16:19Z","timestamp":1781608579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-025-00464-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["464"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00464-z","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"26 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted with the approval of the Ethics Committee of Fujita Health University (ethical approval number: HM23-478; date on approval: April 15, 2024). The requirement for informed consent was waived given the retrospective design of the study. We used an opt-out method based on the ethics committee approval requirements and national ethical guidelines; additionally, patients could obtain information regarding the study from the institution\u2019s website.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}